Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 5/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17610102 | 1.00 | LGALS1 (0.36) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL6837637 | 1.00 | LGALS1 (0.36) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL27818667 | 1.00 | LGALS1 (0.36) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL2236561 | 0.87 | CDA (0.35) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8857040 | 0.87 | CDA (0.35) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8857031 | 0.87 | CDA (0.35) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18789291 | 0.87 | CDA (0.35) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL967650 | 0.81 | LGALS1 (0.38) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL10344684 | 0.81 | LGALS1 (0.38) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL25432185 | 0.78 | LGALS1 (0.39) | LGALS1LGALS3LGALS9LGALS8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116411353-A | Synthesis method of DNA coding compound oxo-glycoside | 成都先导药物开发股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| EP-2260101-B1 | MICRORNA (MIRNA) MIR-21 FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES | UNIV WUERZBURG J MAXIMILIANS (DE) | 2013-05-29 | — | — | EP | claimed |
| CN-116411353-A | Synthesis method of DNA coding compound oxo-glycoside | 成都先导药物开发股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-113264967-B | Programmed death ligand-1 targeted compound and preparation method and application thereof | 江苏省原子医学研究所 | 2023-04-18 | — | — | CN | disclosed |
| CN-1240380-C | Phase transfer catalyzed glycosidation of indolopyrrolocarbazoles | MERCK & CO INC (US) | 2006-02-08 | — | — | CN | disclosed |
| CN-1482908-A | Phase transfer catalyzed glycosidation of an indolocarbazole | — | 2004-03-17 | — | — | CN | disclosed |
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | PETRILLO DANIEL E (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1333826-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6555677-B2 | Preparing preferential compound; incubate sugar with activating agent, couple activated sugar with preferential compound, recover compound | MERCK & CO., INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| WO-2002036601-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | LGALS1 802/4885LGALS3 362/4885LGALS9 1065/4885 |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | LGALS1 802/4885LGALS3 362/4885LGALS9 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.